08/20/2026
IF THE FDA... If the FDA truly followed reliable science, its ni****ne policy would look very different. The strongest evidence we have shows that switching from smoking to va**ng dramatically reduces exposure to toxicants and improves short‑term health outcomes. The National Academies of Sciences, Engineering, and Medicine concluded in “Public Health Consequences of E‑Ci******es” (Eaton et al., 2018) that complete substitution reduces exposure to numerous carcinogens. Biomarker research such as “Biomarkers of Exposure in Adult Smokers Who Switched to E‑Ci******es” (Shahab, Goniewicz et al., Annals of Internal Medicine, 2017) found that smokers who switch show toxicant levels similar to non‑smokers. Emissions studies like “Comparison of the Effects of E‑Cigarette V***r and Cigarette Smoke on Indoor Air Quality” (Goniewicz et al., Ni****ne & To***co Research, 2014) demonstrate that vapour contains far fewer harmful chemicals than smoke. Clinical trials such as “A Randomized Trial of E‑Ci******es versus Ni****ne‑Replacement Therapy” (Hajek et al., New England Journal of Medicine, 2019) show va**ng is nearly twice as effective for quitting as ni****ne patches or gum. Even the EVALI outbreak was shown to be caused by illicit THC oils containing vitamin E acetate, not ni****ne v**es, as confirmed in “Update: Characteristics of Patients in a National Outbreak of EVALI” (Layden et al., NEJM, 2020).
If the FDA acted on this evidence, it would clearly communicate that va**ng is far less harmful than smoking, authorise more products that help adults switch, allow adult‑oriented flavours with strong age‑gating, and focus enforcement on illicit markets rather than responsible manufacturers. Reliable science supports harm reduction; political pressure often does not.
A major barrier to harm reduction is the way va**ng is constantly described as a “to***co product.” This conflation is scientifically inaccurate and deeply damaging. Va**ng products contain no to***co, yet the label makes the public believe they carry the same risks as ci******es. The to***co industry benefits from this confusion because it protects cigarette sales and helps them push for regulations that eliminate independent v**e companies while allowing their own expensive, closed‑system devices through. Bloomberg‑funded NGOs benefit because the “to***co product” label supports their abstinence‑only messaging and justifies aggressive restrictions, even when those restrictions push adults back to smoking. When va**ng is framed as “to***co,” harm‑reduction tools are treated as if they were the problem rather than the solution.
This confusion is amplified by the way “ni****ne” is discussed. Ni****ne is routinely portrayed as the harmful element in smoking, even though the danger comes from combustion, tar, and thousands of toxic by‑products created when to***co burns. By treating ni****ne itself as the threat, public messaging makes va**ng appear as dangerous as smoking, even though vapour contains a fraction of the toxicants found in smoke. This narrative works perfectly with the to***co/va**ng conflation: if ni****ne is “the harm,” then anything containing ni****ne can be framed as a “to***co product,” regardless of whether it contains to***co or produces smoke. The to***co industry benefits because fear of ni****ne keeps smokers on ci******es, their most profitable product. Bloomberg‑aligned NGOs benefit because ni****ne‑centric messaging supports their abstinence‑only approach and reinforces the idea that harm‑reduction tools are simply “new ways to get hooked.” The result is a public that fears the wrong thing, misunderstands the science, and remains trapped in the most dangerous form of ni****ne delivery ever invented.
Universities also face pressure to produce negative va**ng research. Large philanthropic funders, including Bloomberg‑aligned organisations, provide grants specifically for youth‑risk studies, creating incentives for researchers to frame va**ng as a public threat rather than a harm‑reduction tool. This pressure can shape study design, limit the scope of research to youth‑centric questions, and discourage investigations into adult switching, toxicant reduction, or real‑world cessation outcomes. When funding streams reward negative findings, the scientific landscape becomes distorted, and the public receives a one‑sided picture that does not reflect the full evidence base.
The cost of continued smoking remains devastating. Ci******es kill half of long‑term users. They cause around 70% of lung‑cancer deaths, drive heart disease, COPD, and stroke, and shorten life expectancy by a decade. In the UK alone, smoking causes roughly 75,000 deaths every year. No other consumer product comes close. When reliable science shows that switching to va**ng slashes toxicant exposure and improves health outcomes, it is vital that regulation reflects reality rather than political pressure or industry manipulation. Harm reduction saves lives. Smoking takes them.
